Protein kinase B (PKB/AKT) has been identified as a promising cancer drug target downstream of PI3 kinase. To find novel inhibitors of PKB/AKT kinase activity for progression as anticancer agents, the authors have used a high-throughput screen based on AlphaScreen™ technology. A known kinase inhibitor, the isoquinoline H8, was used as a positive control with mean inhibition in the screen of 43.4% ± 13.1%. The performance of the screen was highly acceptable with Z´ and Z factors of 0.83 ± 0.07 and 0.75 ± 0.04, respectively. A number of confirmed hits (~0.1% hit rate) were identified from 63,500 compounds screened. Five compounds have previously been described as PKB inhibitors, demonstrating the ability of the assay to find authentic inhibitors of the enzyme. Five hits had the potential to interfere with the assay signal and were deemed to be false positives. Two compounds were nonspecific inhibitors of PKB as enzyme inhibition in a filter-based assay was markedly reduced in the presence of 0.01% Triton X100. The authors now include an interference assay during hit confirmation procedures and check compound activity in the presence of Triton X100 in an attempt to eliminate nonspecific aggregators at an early stage. (Journal of Biomolecular Screening 2006:822-827) 
INTRODUCTION
A CTIVATION OF THE PHOSPHATIDYLINOSITOL 3-KINASE (PI3 kinase) pathway leads to cellular survival, growth, and proliferation through a variety of mechanisms and is frequently deregulated in cancer. 1 Activation of the serine threonine protein kinase B (PKB/AKT) downstream of PI3 kinase by phosphorylation on both serine 473 and 308 has an essential role in mediating PI3 kinase-dependent signaling. 2 In tumor cells, constitutive activation of the PI3 kinase pathway occurs through a number of mechanisms, 3 including activating mutation of the gene that encodes the p110α subunit of PI3 kinase and genetic loss or inactivation of the lipid phosphatase PTEN.
The strong association between deregulation of the PI3 kinase pathway and tumorigenesis provides compelling evidence for therapeutic intervention of this pathway for the treatment of cancer. 3, 4 The evidence that validates PKB/AKT as a cancer drug target includes overexpression of the enzyme leading to activation of the pathway and inhibition of tumor cell growth following loss of PKB/AKT function. [1] [2] [3] [4] [5] Small-molecule inhibitors of PKB/AKT may thus have an important role to play in the treatment of cancer. 3, 4 Several inhibitors of PKB/AKT have been described, 4 including the nonselective, adenosine triphosphate (ATP) competitive, isoquinoline inhibitors H8 and H89. 6 We have recently described the properties of 2 small-molecule inhibitors of PKB/AKT kinase based on the isoquinoline structure. 7 High-throughput screening (HTS) and structure-based design based on the available crystal structure of PKB/AKT (β) 8, 9 provide important tools for the discovery and design of small-molecule inhibitors of PKB/AKT. As part of an integrated drug discovery project, we have carried out an HTS to find novel inhibitors of PKB/AKT kinase activity for progression as antitumor agents using the homogeneous AlphaScreen™ format. 10 The assay, based on the enzymatic phosphorylation of a biotinylated PKB/AKT substrate peptide, depends on the binding of the peptide to streptavidin-coated donor beads and recognition of substrate phosphorylation by a phosphospecific antibody that is bound by protein A-conjugated acceptor beads. The assay signal is only transferred to acceptor beads once the peptide is phosphorylated. The characteristics of the assay and its performance in a screening campaign are reported. In addition, the properties of some of the compounds identified in the screen are described.
MATERIALS AND METHODS
White 384-well OptiPlates were purchased from PerkinElmer Life Sciences (Beaconsfield, Bucks, UK), and white 384-well nonbinding surface (NBS) plates were purchased from Corning (Sunderland, UK). Multiscreen-PH (MAPH NOB) filter plates were purchased from Millipore (Watford, UK). AlphaScreen™ Protein A Generic IgG Detection kits, γ 33 P-adenosine 5´-triphosphate (γ 33 P-ATP), and Microscint 20 liquid scintillant were purchased from PerkinElmer. Biotinylated Crosstide, 11 KGSGSGRPRTSSFAEG, was purchased from Upstate Cell Signaling Solutions (Dundee, UK) and AKTide 2T (ARKRERTYSFGHHA) from Merck Biosciences (Nottingham, UK). Anti-phospho-GSK3-α/β (Ser21/9) antibody (#9331) was purchased from Cell Signaling Technology (Beverley, MA). Activated recombinant human PKB-PIFβ and PKB-S474D (corresponding to residues 146-481 of PKBβ with a serine 474 to aspartate replacement) were expressed and purified as described earlier. 8, 9 H8 and H89 were purchased from CalbioChem, Merck Biosciences (Nottingham, UK). Staurosporine and all other materials were purchased for Sigma-Aldrich (Poole, Dorset, UK) and were of the highest purity available.
The compound library contained a selection of diverse small molecules purchased from various commercial suppliers, including a library of kinase-directed compounds. In addition, the collection contained compounds archived in-house and through Cancer Research UK.
AlphaScreen™ assay
The assay was performed in white, nonbinding surface 384well plates in assay buffer, pH 7.4, which consisted of HEPES (20 mM), MgCl 2 (15 mM), DTT (1 mM), Tween-20 (0.1%) and glycerol (10%). Compounds (final concentration 30 µM, 0.3% DMSO) or vehicle control (final concentration 0.3% DMSO) were added to the central 320 wells of a 384-well plate from a daughter compound plate (200 µM in 2% DMSO). PKB-PIFβ (final concentration 0.2 nM), diluted in assay buffer, was added to all the wells on the plate (except for wells E1 to P1 and A24 to L24). Anti-phospho-GSK3-a/β (Ser21/9) antibody (final concentration 0.15 nM) was added to all wells on the plate. Biotinylated Crosstide (final concentration 20 nM) and ATP (final concentration 30 µM) diluted in assay buffer were then added to all wells of the plates, and the plate was incubated for 70 min at room temperature. A MiniTrak V (PerkinElmer) was used for compound and reagent addition. Each 384-well plate contained 32 wells for total enzyme activity (T, columns 2 and 23). Columns 1 and 24 were used for no enzyme blanks (B, 24 wells) and positive controls (H8 at a concentration of 30 µM,
wells). Streptavidin-coated donor beads and protein
A-conjugated acceptor beads were added together (final concentration of each type of bead 10 µg/mL) and diluted in HEPES (100 mM) buffer, pH 7.4, containing EDTA (100 mM) and bovine serum albumin (BSA) (0.25%). After an overnight incubation, the assay endpoint was measured using a Multilabel Fusion-Alpha microplate reader (PerkinElmer). To avoid premature activation of the donor beads by environmental light exposure, the bead dispense was performed in a laboratory that had been darkened through the use of blackout blinds and in the absence of overhead lighting. For the overnight bead incubation and reading steps, assay plates were placed in the instrument stacker and wrapped in foil to avoid environmental light exposure. To stabilize the temperature and to avoid drift across the plates, each plate was incubated in the instrument for 10 min prior to the signal being read.
Filter assay
The filter plate kinase reaction was performed using MOPS (20 mM) (pH 7.2), β-glycerophosphate (25 mM), EDTA (5 mM), MgCl 2 (15 mM), sodium orthovanadate (1 mM), and dithiothreitol (1 mM) with the addition of ATP (30 µM) as assay buffer. Compounds or vehicle control (5 µL) were added to a 96-well polypropylene filter plate, followed by substrate mix (10 µL), which contained 33 P-ATP (0.35 µCi/well) and AKTide-2T (62.5 µM). The enzyme mix (0.3 nM PKB-Pifβ in assay buffer) was added (10 µL) and the plate incubated at room temperature for 20 min. The reaction was stopped by the addition of 2% orthophosphoric acid (30 µL). The stopped reaction was transferred to the wells of a prewetted phosphocellulose filter plate, the contents of each well filtered and washed twice with orthophosphoric acid (0.5%). Microscint 20 scintillant (25 µL) was added and the plate read for 30 sec using a TopCount NXT microplate counter (PerkinElmer).
Calculations
Primary screening data were analyzed in Excel (Microsoft) and subsequently processed using OMMM/RS 3 (Accelrys, Cambridge, UK). Percentage inhibition was calculated as follows: (100 -(S -B)/(T -B)) · 100, where S represented the counts for each compound well, B the counts in the wells containing no enzyme, and T the counts in the total activity wells. Z´ factors and Z factors were calculated as described previously. 12 
RESULTS AND DISCUSSION
The homogeneous AlphaScreen™ assay format has previously been described for the measurement of generic serinethreonine kinase activity. 10 Here we describe the specific application of this assay format to PKB/AKT kinase.
Two different preparations of activated PKB/AKT enzyme were used in initial assay development. PKBβ S474D 8 was used to determine the ATP concentration-dependence for PKB/AKT. Increased enzyme activity was observed over the concentration range used (0-100 µM) with an approximate Km of 30 µM. This Km is consistent with the value of 40 µM previously reported. 6 Assay development was subsequently carried out using 30 µM ATP and PKB-PIFβ 9 as this enzyme was available in larger quantities and had marginally greater enzymatic activity than PKBβ S474D.
A wide signal window (Z´ ~0.9) between total enzyme activity versus no enzyme control was obtained using the Crosstide peptide substrate and corresponding antibody (anti-phospho-GSK3-α/β (Ser21/9)). Blank values were less than 1000 counts, and the signal reached a plateau at 20 to 30 nM Crosstide, which is approximately equivalent to the binding capacity of the streptavidin beads. 10 The substrate was used at a concentration of 20 nM in all later experiments. The PKB-PIFβ enzyme showed linear kinetics over the concentration range 0 to 1 nM and over 60 min at an enzyme concentration of 0.5 nM.
In these initial optimization experiments, the donor and acceptor beads were incubated for only 1 h following enzyme incubation. When batches of plates are being assayed in a screen, it is important to know how long it takes for the bead/assay components to interact and to show that the signal obtained and enzyme inhibition is thereafter constant. Figure 1 shows the effect of increasing the time of the bead incubation over 1200 min. The assay signal increased rapidly up to ~270 min but increased by only an additional 10% following a subsequent overnight incubation. A similar profile was observed when the enzyme reaction was inhibited with the isoquinoline H89 enzyme inhibitor (1 µM), resulting in a 30% to 45% inhibition of PKB/AKT activity throughout the time course. This compound has previously been shown to have an IC 50 of 2.5 µM against PKB/AKT. 6 The no-enzyme controls (B) gave low background counts throughout this time course, indicating the high specificity of the antibody for phosphorylated peptide. Two additional positive controls, the nonselective kinase inhibitor staurosporine and H8, inhibited the enzyme activity with IC 50 values of 0.07 µM and 18 µM, respectively.
The costs of reagents used in the assay are crucial for HTS, and the effects of reducing the antibody and bead concentrations on assay performance were investigated. The amount of antibody in the assay could be reduced from 1.0 nM to 0.2 nM in the well and the bead concentrations reduced by half without compromising the signal window. For example, at 0.5 nM PKB-PIFβ, the signal was reduced by approximately 50% by halving the amount of beads used, but the total counts and size of the signal window (Z´ = 0.9) remained highly acceptable.
The final protocol used in the screen is described in Materials and Methods. In the course of assay validation, we included 3 simple precautionary steps in the protocol that helped to improve plate-to-plate and within-plate assay variation. The first of these was to use reduced ambient light levels to minimize activation of the donor beads prior to their excitation in the plate reader. Second, during the overnight incubation to allow equilibrium to take place in the bead reactions, the plates were wrapped in foil to avoid exposure to light. Last, to reduce drift across the plate, a delay period was used so that each plate was incubated in the instrument for 10 min prior to measurement of the signal. Approximately 63,500 compounds, at a final concentration of 30 µM in 16 batches, were screened (Fig. 2) . Plateto-plate and batch-to-batch reproducibility was acceptable, and the overall percent coefficient of variation (%CV) for the total activity wells on each plate was 7.5 ± 1.4 (mean ± SD). The mean Z´ factor for the whole screen was 0.83 ± 0.07 (mean ± SD), and the mean Z factor was 0.75 ± 0.04 (mean ± SD). The PKB/AKT inhibitor H8, used as the positive control on each plate at a final concentration of 30 µM, gave a mean percent inhibition throughout the screen of 43.4 ± 13.1 (mean ± SD).
A total of 42 compounds were identified as confirmed hits in the screen, equivalent to an overall hit rate of ~0.1%. The relative potencies in AlphaScreen™ and a filter-based assay of 36 compounds, selected based on their physicochemical properties, were determined. A total of 18 compounds inhibited PKB/AKT with a potency less than 50 µM.
Assay interference is a well-known problem in HTS. An examination of the structures of the primary hits identified 5 compounds that were considered to be false positives ( Table 1) azo dyes CCT007596 and CCT010173) and quenching of the singlet oxygen through redox chemistry. Two of the compounds, CCT012319 and CCT012320, contained a biotin-like moiety and were likely to compete with the binding of the biotinylated peptide to the streptavidin-coated donor beads. Indeed, these compounds have been identified as false positives in subsequent AlphaScreen™ screens run in our laboratory and were inactive in the filter assay. The detergent-like compound CCT010431, although active in the filter assay (1.7 µM), was chemically unattractive, and it was likely to have nonspecific effects on both assay.
We identified in the screen a number of compounds that were structurally similar to previously reported inhibitors of this enzyme, and their identification provided validation that the screen was capable of identifying authentic PKB/AKT inhibitors. Four of these were toxoflavins (IC 50 0.09-8.5 µM), a series of compounds previously reported to have activity against a number of kinases, including PKB (PCT Intl. Appl. WO 2004007498 and WO 2004007499) . Another confirmed active (IC 50 = 28.3 µM) was an analogue of rhodanine, a structural class that has also been reported to provide inhibitors of PKB/AKT (PCT Intl. Appl. WO2003043998). Table 2) showed properties consistent with the notion of promiscuous inhibition through aggregation of the compounds. 13 In the filter assay, CCT020227 and CCT018264 (a close analogue of the hit CCT018641, IC 50 = 30.4 µM) inhibited PKB/AKT with a potency of 10 and 50.5 µM, respectively. However, the activity of both compounds was lost when assayed in the presence of 0.01% Triton X100. 14 Under the same conditions, the activity of H8 was unaffected.
One mechanism for promiscuous inhibition is thought to be through nonspecific protein aggregation resulting in apparent enzyme inhibition. Although possessing high lipophilicity (CCT020227 MW = 381, ClogP = 4.7; CCT018264 MW = 386, ClogP = 6.2), these 2 compounds are not members of structural classes previously reported as particularly prone to aggregation. 13, 15 In view of the number of interfering compounds identified in this screen, we now routinely simultaneously test cherry-picked compounds for AlphaScreen™ interference to eliminate false positives at the hit confirmation stage. This is achieved by using an assay in which the phosphorylated substrate peptide is used in the absence of enzyme to complete the biomolecular interaction. The presence of AlphaScreen™ interfering compounds results in the loss of signal. In addition, cherry-picked compounds are also tested in the presence of Triton X100 so that, where possible, aggregators can also be eliminated at an early stage.
In summary, we have optimized and run an HTS using AlphaScreen™ reagents to identify inhibitors of PKB/AKT kinase activity. Some simple precautionary steps were included in the protocol to prevent potentially deleterious quenching effects of ambient light and temperature-dependent effects across the plate. The overall performance of the screen was highly acceptable and robust, and previously described inhibitors of PKB/AKT kinase activity were successfully identified. A number of hit compounds that were thought to interfere with the generation of the assay signal were identified as well as 2 compounds that were nonspecific protein aggregators. Following hit identification using an AlphaScreen™ format, we now routinely test for AlphaScreen™ interference and the potential for nonspecific aggregation of proteins at an early stage of hit validation.
ACKNOWLEDGMENTS
The work of the Cancer Research UK Centre for Cancer Therapeutics is funded primarily by Cancer Research UK [CUK] Programme Grant C309/A2187. Paul Workman is a 
